Krystal Biotech diskutieren
Krystal Biotech
WKN: A2JH2F / Symbol: KRYS / Name: Krystal Biotech / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
148,15 €
-1,56 %
(Vom Mitglied beendet)
SecteurRecherche biotechnologique et médicale Agenda 28/11 | 15:30 Présentation
Operates as a biopharmaceutical company which provides therapies for rare and orphan diseases
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases.
It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments.
The company was founded by Suma M. Krishnan in December 2017and is headquartered in Pittsburgh, PA.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases.
It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments.
The company was founded by Suma M. Krishnan in December 2017and is headquartered in Pittsburgh, PA.
Nombre d'employés : 12 personnes.
(Vom Mitglied beendet)
Buy Krystal Biotech
Buy mit Kursziel 60,0
Kursziel geändert auf 70,0
Buy beendet
Sell Krystal Biotech
Buy Krystal Biotech
Buy Krystal Biotech
Buy Krystal Biotech
Sell Krystal Biotech
Sell Krystal Biotech
Sell Krystal Biotech
Buy mit Kursziel 55,0
Sell mit Kursziel 37,0
Sell Krystal Biotech
Sell Krystal Biotech
Sell mit Kursziel 50,0
Neueste Beiträge
DirectorDealer in Brockhaus Capital Mgmt AG diskutieren